Kamila Zglejc-Waszak

Dr. Kamila Zglejc-Waszak

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2021 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
KZKamila Zglejc-Waszak
Kamila Zglejc-Waszak
KMKonark Mukherjee
Konark Mukherjee
JJJudyta Juranek
Judyta Juranek


Verified
Journal Article
Open access
PDF file
NNNatalia Nowicka
Natalia Nowicka
KSKamila Szymanska
Kamila Szymanska
JJJudyta Juranek
Judyta Juranek
KZKamila Zglejc-Waszak
Kamila Zglejc-Waszak
AKAgnieszka Korytko
Agnieszka Korytko
JWJoanna Wojtkiewicz
Joanna Wojtkiewicz
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive degeneration of upper and lower motor neurons that causes paralysis and muscle atrophy. The pathogenesis of the disease is still not elucidated. Receptor for Advanced Glycation End Product (RAGE) is a major component of the innate immune system and has implications in ALS pathogenesis. Multiple studies suggest the role of RAGE and its ligands in ALS. RAGE and its ligands are overexpressed in human and murine ALS motor neurons, astrocytes, and microglia. Here, we demonstrated the expression of RAGE and its ligands during the progression of the disease in the transgenic SOD1 G93A mouse lumbar spinal cord. We observed the highest expression of HMGB1 and S100b proteins at ALS onset. Our results highlight the potential role of RAGE and its ligands in ALS pathogenesis and suggest that some of the RAGE ligands might be used as biomarkers in early ALS diagnosis and potentially be useful in targeted therapeutic interventions at the early stage of this devastating disease.

18 July 2023 in Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
KZKamila Zglejc-Waszak
Kamila Zglejc-Waszak
KMKonark Mukherjee
Konark Mukherjee
AKAgnieszka Korytko
Agnieszka Korytko
Bogdan LewczukBogdan Lewczuk
Bogdan Lewczuk
APAndrzej Pomianowski
Andrzej Pomianowski
JJJudyta Juranek
Judyta Juranek
Multiple molecular pathways including the receptor for advanced glycation end-products-diaphanous related formin 1 (RAGE-Diaph1) signaling are known to play a role in diabetic peripheral neuropathy (DPN). Evidence suggests that neuropathological alterations in type 1 diabetic spinal cord may occur at the same time as or following peripheral nerve abnormalities. We demonstrated that DPN was associated with perturbations of RAGE-Diaph1 signaling pathway in peripheral nerve accompanied by widespread spinal cord molecular changes. More than 500 differentially expressed genes (DEGs) belonging to multiple functional pathways were identified in diabetic spinal cord and of those the most enriched was RAGE-Diaph1 related PI3K-Akt pathway. Only seven of spinal cord DEGs overlapped with DEGs from type 1 diabetic sciatic nerve and only a single gene cathepsin E (CTSE) was common for both type 1 and type 2 diabetic mice. In silico analysis suggests that molecular changes in spinal cord may act synergistically with RAGE-Diaph1 signaling axis in the peripheral nerve. Key messages: Molecular perturbations in spinal cord may be involved in the progression of diabetic peripheral neuropathy. Diabetic peripheral neuropathy was associated with perturbations of RAGE-Diaph1 signaling pathway in peripheral nerve accompanied by widespread spinal cord molecular changes. In silico analysis revealed that PI3K-Akt signaling axis related to RAGE-Diaph1 was the most enriched biological pathway in diabetic spinal cord. Cathepsin E may be the target molecular hub for intervention against diabetic peripheral neuropathy.


19 November 2021 in Life
Verified
Journal Article
Open access
PDF file
JJJulia Jaroslawska
Julia Jaroslawska
AKAgnieszka Korytko
Agnieszka Korytko
KZKamila Zglejc-Waszak
Kamila Zglejc-Waszak
TATomasz Antonowski
Tomasz Antonowski
APAndrzej S. Pomianowski
Andrzej S. Pomianowski
JJJudyta Juranek
Judyta Juranek
The objective of the study was to compare the effects of experimentally induced type 1 or type 2 diabetes (T1D or T2D) on the functional, structural and biochemical properties of mouse peripheral nerves. Eight-week-old C57BL/6 mice were randomly assigned into three groups, including the control (CTRL, chow-fed), STZ (streptozotocin (STZ)-injected), and HFD (high-fat diet (HFD)-fed) group. After 18-weeks of experimental treatment, HFD mice had higher body weights and elevated levels of plasma lipids, while STZ mice developed hyperglycemia. STZ-treated mice, after an extended period of untreated diabetes, developed motor and sensory nerve conduction-velocity deficits. Moreover, relative to control fibers, pre- and diabetic axons were lower in number and irregular in shape. Animals from both treatment groups manifested a pronounced overexpression of nNOS and a reduced expression of SOD1 proteins in the sciatic nerve, indicating oxidative–nitrosative stress and ineffective antioxidant protection in the peripheral nervous system of these mice. Collectively, STZ- and HFD-treated mice revealed similar characteristics of peripheral nerve damage, including a number of morphological and electrophysiological pathologies in the sciatic nerve. While hyperglycemia is a large component of diabetic neuropathy pathogenesis, the non-hyperglycemic effects of diabetes, including dyslipidemia, may also be of importance in the development of this condition.